Putting oncogenes into a developmental context

Cancer Biology and Therapy

Volumn 3, Issue 10, 2004, Pages 942-944

  Felsher, Dean W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

MYC; Oncogene; Transgenic model Tet system; Tumorigenisis

Indexed keywords

GENE PRODUCT;

AGE DISTRIBUTION; CANCER GENETICS; CARCINOGENESIS; CELL PROLIFERATION; EPIGENETICS; EXPERIMENTAL MODEL; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HYPERTROPHY; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; ONCOGENE; ONCOGENE MYC; PATHOGENESIS; REVIEW; TRANSGENIC ANIMAL; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; ONCOGENES;

EID: 21244491879     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.10.1307     Document Type: Review

References (19)

1. The International agency for the research of cancer. Cancer Incidence in Five Continents. Volumes I-VII 1997.
2. Klein G, Klein E. Conditioned tumorigenicity of activated oncogenes. Cancer Res 1986; 46:3211-24.
3. Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, et al. Developmental Context Determines Latency of MYC-Induced Tumorigenesis. PLoS Biol 2004; 2:e332.
4. Pelengaris S, Khan M, Evan G. c-Myc: More than just a matter of life and death. Nat Rev Cancer 2002; 2:764-76.
5. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12:2984-91.
6. INK4a. Cell 1997; 88:593-602.
7. Johnston LA, Prober DA, Edgar BA, Eisenman RN, Gallant P. Drosophila myc regulates cellular growth during development. Cell 1999; 98:779-90.
8. 2 arrest of normal fibroblasts. Proc Natl Acad Sci USA 2000; 97:10544-8.
9. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 1999; 96:3940-4.
10. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, et al. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003; 101:2797-803.
11. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13:2658-69.
12. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001; 15:2069-82.
13. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11.
14. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Borowsky AD, Ruebner B, Cardiff RD, Bishop JM, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; Epub ahead of print.
15. MH, Chen CJ, Lai MS, Hsu HM, Wu TC, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855-9.
16. Abou-Elella A, Gramlich T, Fritsch C, Gansler T. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol 1996; 9:95-8.
17. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297:102-4.
18. Felsher DW. Cancer revoked: Oncogenes as therapeutic targets. Nat Rev Cancer 2003; 3:375-80.
19. Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L, Jaenisch Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004; 18:1875-85.